Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners
Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with additional participation from other existing investors. The funds from the Series B financing will further advance Syntimmune’s clinical development program.
Most Recent Posts:
Announcing the Brigham Ignite Ignitable Ideas Series
Brigham Ignite is pleased to announce the Ignitable Ideas Series, a virtual educational series for Mass General…
Novel blood test combined with mammography finds cancers sooner, informing treatments and preventing overdiagnoses
Experienced innovator’s technology reduces false-positive results from imaging With plenty of innovations under his belt, David…
Ten Projects Advance at 4th Annual MESH Innovation Teams’ ‘Problem Day’
Top Finalists to Enter Yearlong Program Guiding Their Innovations Aimed at Enhancing Patient Care It’s surely…
